Analysis ReDS technology by use Health Technology Assessment modelling, quantity and optimization methods

Pharmacy Practice

  • Roza Yagudina1Department of Organization of Medical Provision and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.
  • Andrey Kulikov1Department of Organization of Medical Provision and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.
  • Alex Borodin2Department of Finance of Sustainable, Plekhanov Russian University of Economics, 117997 Moscow, Russia.
  • Vyacheslav Serpik1Department of Organization of Medical Provision and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.
  • Marina Protsenko1Department of Organization of Medical Provision and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.
  • Irina Vygodchikova3Department of Differential Equations & Mathematic Economics, National Research Saratov State University Chernyshevsky, 410012, Saratov, Russia.

Volume 23 Issue 1 Pages 1-15

DOI: 10.18549/PharmPract.2025.1.3059

Abstract

Background: The specificity of CHF is a high rate of recurrent hospitalizations for acute decompensation of heart failure (ADHF). One of the important aspects of monitoring the patient’s condition is monitoring the volemic status - identifying and determining the degree of stagnation for the timely optimization of the treatment regimen in order to prevent re-hospitalization. In this regard, of great interest is a new technology for non-invasive measurement of fluid levels in the lungs, implemented in a medical product under the ReDS brand (manufactured by Sensible Medical, Israel). ReDS™ (from remote dielectric sensing) technology is a quantitative, non-invasive method for measuring total lung fluid volume in patients with fluid drainage problems, including those with heart failure. It may be implemented at inpatient, outpatient and pharmacy levels. The results of the assessment showed that at a given level of implementation of ReDS technology, the number of readmissions at the inpatient level will decrease from 375 703 to 252 208 per year, and at the outpatient level from 375 703 to 252 208 per year. This corresponds to a decrease in the annual cost of recurrent hospitalizations from 24.93 billion rubles. respectively to 20.96 (by 15.9%) billion rubles. and 19.70 billion rubles. (21.0% reduction, including additional costs for patient visits to measure for ReDS). At the same time, one-time costs for the purchase of 1 234 units of a ReDS medical device for an outpatient level or 1 129 units of a ReDS medical device for an inpatient level amount to 12.06 billion rubles or 11.04 billion rubles, respectively. The results of the “budget impact” analysis (taking into account the discount factor of 3.5%) of the introduction of ReDS technology at the outpatient level demonstrate that over 7 years it provides cost savings in the amount of 20.33 billion rubles, up to 45.92 billion rubles, and at the stationary level – 13.61 billion rubles.

Keywords

  • health technology assessment
  • optimization
  • heart failure
  • medical device
  • remote dielectric sensing
  • outpatient level
  • inpatient level
Pharmacy Practice

Loading…